The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial
2011
Background Our phase III clinical trial of
pirfenidonefor patients with
idiopathic pulmonary fibrosis(IPF) revealed the efficacy in reducing the decline of
vital capacity(VC) and increasing the
progression-free survival(PFS) time by
pirfenidone. Recently, marginal decline in forced VC (FVC) has been reported to be associated with poor outcome in IPF. We sought to evaluate the efficacy of
pirfenidonefrom the aspects of 5% change in VC.
Keywords:
-
Correction
-
Source
-
Cite
-
Save
27
References
74
Citations
NaN
KQI